MSD cancels research into atherosclerosis using new drug

Merck Sharp and Dohme (MSD) has stopped research into a treatment for atherosclerosis, its development partner, Arena Pharmaceuticals, has revealed.

The two companies had been working on a niacin receptor agonist called MK-0354, which reached phase II clinical trials.

However, following the results of one study involving patients with dyslipidaemia, MSD decided not to continue to develop MK-0354 for the treatment of atherosclerosis. In spite of this, research will continue to find other possible uses for the compound, in addition to the identification of different niacin agonists.

Jack Lief, president and chief executive officer of Arena, remarked: “The data from the clinical trials of MK-0354 have provided valuable information and add to our understanding of the niacin receptor as we continue to evaluate its therapeutic potential.”

He added that he was “pleased” that MSD would continue its research programme.

Kathleen Metters, senior vice president of basic research at MSD laboratories, said her company was looking forward to further researching the potential of niacin agonists with Arena.

Atherosclerosis can affect individuals aged in their 20s and it increases with age, according to NetDoctor.co.uk. The website claims that family history, smoking, hypertension, cholesterol, body weight and diabetes are all risk factors.